home / stock / sttk / sttk quote
Last: | $3.64 |
---|---|
Change Percent: | 1.25% |
Open: | $3.94 |
Close: | $3.64 |
High: | $3.99 |
Low: | $3.63 |
Volume: | 385,895 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.64 | $3.94 | $3.64 | $3.99 | $3.63 | 385,895 | 07-02-2024 |
$3.99 | $3.96 | $3.99 | $4.14 | $3.66 | 582,576 | 07-01-2024 |
$3.86 | $3.76 | $3.86 | $3.98 | $3.57 | 6,403,816 | 06-28-2024 |
$3.75 | $4.11 | $3.75 | $4.42 | $3.68 | 838,122 | 06-27-2024 |
$3.79 | $3.51 | $3.79 | $3.83 | $3.345 | 551,421 | 06-26-2024 |
$3.555 | $3.83 | $3.555 | $3.9 | $3.55 | 598,810 | 06-25-2024 |
$3.955 | $4.35 | $3.955 | $4.38 | $3.91 | 657,446 | 06-24-2024 |
$4.37 | $4.18 | $4.37 | $4.44 | $4.15 | 460,485 | 06-21-2024 |
$4.165 | $4.52 | $4.165 | $4.59 | $4.12 | 460,828 | 06-20-2024 |
$4.59 | $5 | $4.59 | $5.05 | $4.535 | 566,750 | 06-19-2024 |
$4.59 | $5 | $4.59 | $5.05 | $4.535 | 566,750 | 06-18-2024 |
$4.98 | $5.92 | $4.98 | $6.04 | $4.77 | 688,673 | 06-17-2024 |
$6.19 | $6.81 | $6.19 | $6.845 | $6.12 | 510,703 | 06-14-2024 |
$6.84 | $6.61 | $6.84 | $6.99 | $6.59 | 246,534 | 06-13-2024 |
$6.64 | $6.94 | $6.64 | $6.97 | $6.54 | 381,876 | 06-12-2024 |
$6.74 | $6.68 | $6.74 | $6.87 | $6.5 | 320,103 | 06-11-2024 |
$6.7 | $7.02 | $6.7 | $7.135 | $6.59 | 385,945 | 06-10-2024 |
$7.02 | $7.2 | $7.02 | $7.45 | $7.02 | 118,705 | 06-07-2024 |
$7.26 | $7.38 | $7.26 | $7.49 | $6.9672 | 165,134 | 06-06-2024 |
$7.39 | $7.2 | $7.39 | $7.46 | $7.11 | 128,780 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-06-14 19:15:01 ET BTIG analyst issues NEUTRAL recommendation for STTK on June 14, 2024 05:34PM ET. STTK was trading at $6.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontli...
AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmun...